New drug brensocatib offered to bronchiectasis patients who completed key trial
NCT ID NCT05344508
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study provides early access to brensocatib, an experimental tablet, for people with non-cystic fibrosis bronchiectasis who finished the ASPEN trial. Participants must have already taken brensocatib without serious side effects. The goal is to offer continued treatment while more data is gathered.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Brensocatib tablets
- What this could lead to
- If successful, this could provide a new treatment option to control symptoms and reduce flare-ups in people with non-CF bronchiectasis.
- What could go wrong
- This is an early-access study, not a large trial. It only includes patients who already tolerated brensocatib, so results may not apply to everyone. Side effects are still possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
12 to 85 years
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participant had agreed to provide their informed consent to participate per local requirements. * Participant had successfully completed Clinical Trial INS 1007-301 ASPEN, including the End of study Visit 12 prior to receiving treatment. * Requests for Post-Trial access for brensocatib had come from ASPEN investigator. * Had received brensocatib treatment. Exclusion Criteria: * Participant had experienced a serious adverse event deemed to be related to brensocatib during the study and required permanent participant is continuation. * The participant is immunocompromised or chronically treated with any investigational or commercialized immunomodulatory agent that is directed to any component of the adaptive or innate immune systems. Note: The use of any immunomodulatory agents (including but not limited to: bortezomib, ixazomib, thalidomide, cyclophosphamide, mycophenolate, Janus kinase inhibitors, IFN-γ, and azathioprine) is prohibited during the program. * The participant had undergone continuous use of high dose non-steroidal anti-inflammatory drugs. * The participant had undergone chronic use of systemic steroids for any chronic condition, except steroids with topical anti-inflammatory activities (ie, oral budesonide). * Participant had planned to receive live attenuated vaccines during the program (treatment must be postponed until 4 weeks after the last dose of drug). * Participant had planned to use investigational drugs.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non-cystic fibrosis bronchiectasis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a Pulsed-Air device revolutionize mucus clearance for bronchiectasis?
- A vibrating vest may help children with damaged lungs breathe easier
- Can a new biologic drug delay dangerous lung Flare-Ups?
- Inhaled experimental drug targets tough lung infections
- New drug trial aims to tame chronic lung infections
- Scientists develop risk score to forecast bronchiectasis attacks